Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

Saved in:

Bibliographic Details
Main Authors:	Christian Stoess, Aleksandra Leszczynska, Lin Kui, Ariel E. Feldstein
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-10-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	pyroptosis gasdermins liver steatotic liver disease steatohepatitis MASH
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2024.1461581/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Caspase 3 proteolytically inactivates gasdermin Ec and inhibits pyroptosis in an early vertebrate
by: Xin Tian, et al.
Published: (2025-06-01)

Gasdermin D-mediated neutrophil pyroptosis drives inflammation in psoriasis
by: Jian Liu, et al.
Published: (2024-12-01)

Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells
by: William G. Herrick, et al.
Published: (2025-07-01)

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
by: Barbora Nováková, et al.
Published: (2025-08-01)

Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice
by: Kim B. Pedersen, et al.
Published: (2025-05-01)

Neobractatin and Trametinib Synergistically Induce Apoptosis and Gasdermin E‐Dependent Pyroptosis in Pancreatic Cancer Cells
by: Jiaqi Tan, et al.
Published: (2025-07-01)

Estimation of noncanonical pyroptosis biomarkers gasdermin D and caspase 4 in gingiva of periodontitis and diabetes patients: An observational cross-sectional study
by: Lalitha Tanjore Arunachalam, et al.
Published: (2024-11-01)

Gasdermin D‐Mediated Pyroptosis Exerts Two Opposite Effects of Resisting Enzymatic Digestion and Expanding Inflammatory Response in Acute Pancreatitis
by: Chaoxu Liu, et al.
Published: (2025-08-01)

Gasdermin D is activated but does not drive neurodegeneration in SOD1G93A model of ALS: Implications for targeting pyroptosis
by: Georgia Gunner, et al.
Published: (2025-10-01)

Exploiting gasdermin-mediated pyroptosis for enhanced antimicrobial activity of phage endolysin against Pseudomonas aeruginosa
by: Dorota Kuc-Ciepluch, et al.
Published: (2025-01-01)

Etoposide Treatment of Cancer Cell Lines Results in Nuclear Localisation of Cleaved Gasdermin D
by: Soukaina Imlilss, et al.
Published: (2024-12-01)

Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-03-01)

Pyroptosis‐Inducing Biomaterials Pave the Way for Transformative Antitumor Immunotherapy
by: Hao Yin, et al.
Published: (2024-12-01)

Pterostilbene induces pyroptosis in mouse breast cancer cells through the caspase-3/Gasdermin E signaling pathway and reshapes the tumor immune microenvironment
by: Xiaoxia Huang, et al.
Published: (2025-09-01)

Functional Materials Targeted Regulation of Gasdermins: From Fundamentals to Functionalities and Applications
by: Luyao Tian, et al.
Published: (2025-04-01)

Association of Index and Changes in Fibrosis-4 Score With Outcomes in Metabolic Dysfunction-Associated Steatohepatitis
by: Semiu O. Gbadamosi, et al.
Published: (2025-01-01)

Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities
by: Rui Miao, et al.
Published: (2025-04-01)

Understanding the mechanisms of hypoxia-induced tissue damage in fish: The role of GasderminEa/b in Larimichthys crocea
by: Lin Wang, et al.
Published: (2025-01-01)

Machine Learning-Based Non-Invasive Prediction of Metabolic Dysfunction-Associated Steatohepatitis in Obese Patients: A Retrospective Study
by: Jie Chen, et al.
Published: (2025-04-01)

Biological and pharmacological roles of pyroptosis in pulmonary inflammation and fibrosis: recent advances and future directions
by: Ya Liu, et al.
Published: (2024-12-01)

From Inflammasomes to Pyroptosis: Molecular Mechanisms in Chronic Intestinal Diseases — Opportunity or Challenge?
by: Fang J, et al.
Published: (2025-03-01)

Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050
by: Jincheng Tang, et al.
Published: (2025-07-01)

Pyroptosis and its therapeutic potential
by: I. A. Odintsova, et al.
Published: (2024-07-01)

Soluble Siglec-9 Improves Intestinal Barrier Function in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis
by: Hisanori Muto, et al.
Published: (2025-05-01)

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
by: Caesar Ferrari, et al.
Published: (2024-10-01)

Applications of pyroptosis activators in tumor immunotherapy
by: Xin Bao, et al.
Published: (2024-10-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)

Editorial: Unraveling the links between nutrients and metabolic dysfunction-associated liver disease: insights and implications
by: Bruno Ramos-Molina, et al.
Published: (2024-11-01)

Triggering Pyroptosis in Cancer
by: Daniel E. Johnson, et al.
Published: (2025-02-01)

Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2025-06-01)

Genistein inhibits the release of pro-inflammatory substances from macrophages by suppressing potassium loss- and ROS-mediated caspase-1/gasdermin D pathway activation and pyroptotic cell lysis
by: Meimei Yang, et al.
Published: (2024-12-01)

Inhibiting cathepsin B alleviates acute lung injury caused by sepsis through suppression of pyroptosis in lung epithelial cells
by: Xiaobo Zhang, et al.
Published: (2025-05-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis
by: Saranya C. Reghupaty, et al.
Published: (2025-08-01)

Therapeutic Actions of Hepatocyte Extracellular Vesicles in a Murine Model of Diet-Induced Steatohepatitis with Fibrosis
by: Xinlei Li, et al.
Published: (2025-01-01)

RENAL INJURY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH OBESITY
by: Kellyane Dias CARVALHO, et al.
Published: (2025-05-01)

Advances in gasdermin activation, regulation, and targeted drug development
by: Tai Luo, et al.
Published: (2025-06-01)

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
by: Hee Yeon Kim, et al.
Published: (2025-07-01)

Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
by: Ying Geng, et al.
Published: (2024-11-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)